Literature DB >> 32401203

Long-Term Outcomes from Blind Sac Closure of the External Auditory Canal: Our Institutional Experience in Different Pathologies.

Mordechai Kraus1, Fatemeh Hassannia1, Michael J Bergin1, Khalid Al Zaabi1, John Alexander Rutka1.   

Abstract

OBJECTIVES: This study reports long-term results of blind sac closure of the external auditory canal performed for various pathologies, compares the complication rates and the need for revision surgery.
MATERIALS AND METHODS: This study is a retrospective review. Ninety-six cases of blind sac closure performed for various pathologies were included in this study. The primary pathologies included extensive mucosal disease in an open mastoid cavity, cholesteatoma, skull base lesion, cerebrospinal fluid leak, and osteoradionecrosis of the temporal bone. Preoperative history, postoperative complications, and the need for revision surgery were evaluated.
RESULTS: The most common indication for blind sac closure in our series involved skull base lesions (62.5%). The mean follow-up period was 46 months (4 months - 20 years). The total complication rate related to blind sac closure was 10.4%. The median time between surgery and long-term complications was 5.5 years. Patients with chronic mucosal disease had the highest rate of complications.
CONCLUSION: Blind sac closure of external meatus can be effectively performed for different pathologies. Long-term follow-up with patients is necessary. Patients with chronic mucosal disease have the highest complication rates.

Entities:  

Mesh:

Year:  2020        PMID: 32401203      PMCID: PMC7224430          DOI: 10.5152/iao.2020.7688

Source DB:  PubMed          Journal:  J Int Adv Otol        ISSN: 1308-7649            Impact factor:   1.017


  9 in total

1.  Primary closure of the radical mastoidectomy wound: a technique to eliminate postoperative care.

Authors:  J H T RAMBO
Journal:  Laryngoscope       Date:  1958-07       Impact factor: 3.325

2.  Blind sac closure: a safe and effective management option for the chronically discharging ear.

Authors:  S J Muzaffar; S Dawes; A K Nassimizadeh; C J Coulson; R M Irving
Journal:  Clin Otolaryngol       Date:  2016-03-07       Impact factor: 2.597

3.  Middle ear and mastoid obliteration for cochlear implant in adults: indications and anatomical results.

Authors:  Daniele Bernardeschi; Yann Nguyen; Mustapha Smail; Didier Bouccara; Bernard Meyer; Evelyne Ferrary; Olivier Sterkers; Isabelle Mosnier
Journal:  Otol Neurotol       Date:  2015-04       Impact factor: 2.311

Review 4.  Subtotal petrosectomy: Surgical technique, indications, outcomes, and comprehensive review of literature.

Authors:  Sampath Chandra Prasad; Valeria Roustan; Gianluca Piras; Antonio Caruso; Lorenzo Lauda; Mario Sanna
Journal:  Laryngoscope       Date:  2017-03-27       Impact factor: 3.325

5.  Impact of the surgical wound closure technique on the revision surgery rate after subtotal petrosectomy.

Authors:  Stefan Lyutenski; Burkard Schwab; Thomas Lenarz; Rolf Salcher; Omid Majdani
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-03-25       Impact factor: 2.503

6.  No cerebrospinal fluid leaks in translabyrinthine vestibular schwannoma removal: reappraisal of 200 consecutive patients.

Authors:  M Falcioni; J J Mulder; A Taibah; G De Donato; M Sanna
Journal:  Am J Otol       Date:  1999-09

7.  Middle Ear Obliteration with Blind-Sac Closure of the External Auditory Canal for Spontaneous CSF Otorrhea.

Authors:  Shawn M Stevens; Ryan Crane; Myles L Pensak; Ravi N Samy
Journal:  Otolaryngol Head Neck Surg       Date:  2016-11-17       Impact factor: 3.497

8.  Blind sac closure of the external auditory canal for chronic middle ear disease.

Authors:  Mamtaben Patel; Fiona Louise Loan; Jennifer Rose Lyon; Philip Antony Bird
Journal:  Otol Neurotol       Date:  2014-01       Impact factor: 2.311

9.  Management of chronic otitis by middle ear obliteration with blind sac closure of the external auditory canal.

Authors:  Mario Sanna; Francesco Dispenza; Sean Flanagan; Alessandro De Stefano; Maurizio Falcioni
Journal:  Otol Neurotol       Date:  2008-01       Impact factor: 2.311

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.